— Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected.
— Total revenue soared to $30.12 million from $500 thousand a year ago. The analysts estimated revenue of $29.4 million for the fourth quarter.
— Selling, general and administrative expenses jumped by 65% year-over-year while research and development expenses fell by 25%.
— Looking ahead into fiscal 2020, the company still expects Firdapse net revenues to be in the range of $135-155 million.
— The company expects to report top-line results from the phase 3 trial for myasthenia gravis (MG) patients with autoantibodies to muscle-specific tyrosine kinase (MuSK) in the second quarter of 2020.
— Catalyst expects to report top-line results from the SMA Type 3 proof of concept trial in the second quarter of 2020. It predicts potential approval of New Drug Submission (NDS) for Firdapse to treat LEMS in Canada in the second half of 2020.
— Assuming the MuSK-MG trial is successful, the company hopes to submit a supplemental NDA for Firdapse for MuSK-MG around the end of 2020.
— In the face of the coronavirus Covid-19 outbreak, the company has been asked to provide a continuous uninterrupted supply of Firdapse. As of today, Catalyst has more than an adequate supply of Firdapse ready for shipment in the warehouse to meet patients’ needs through the end of this year.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to